Effectiveness and Efficiency of Mobile Technology in Disease Control of Asthmatic Obese Patients

Hospital Universitario Virgen Macarena33 enrolled

Overview

Single-center open-label randomized pilot study to assess the effectiveness and efficiency of a mobile technology based intervention for asthma and obesity control.

Single-center open-label randomized pilot study to assess the effectiveness and efficiency of a mobile technology based intervention for asthma and obesity control. The interventional group subjects received a mobile device with an ad-hoc designed application (called ASMATIC) which permitted them to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and advice for healthy lifestyle habits, including personalized diet recommendations and exercise monitoring. The device also permits a bidirectional communication between the patient and the study staff for reporting any emerging issues related to the asthmatic condition of the patient, as the need of additional in-personconsultations. The control group is followed-up based on the study site usual clinical practice, without any specific intervention. The primary study objective is to evaluate whether the use of the ASMATIC mobile application use improves parameters of asthma control, obesity control, asthma obese patient's quality of life and if it's associated with savings in health-related costs (efficiency assessment), compared to the usual clinical practice.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Asthma Obesity

Interventions

Mobile App interventionOTHER

The intervention is based on the interventional group subjects use of a mobile device with an ad-hoc designed application (called ASMATIC). This app permit them (in a daily basis) to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and decision support for patient disease self-management; and contains advice on healthy lifestyle habits, including personalized diet recommendations based on clinical criteria and associated recipes. The device also permits the study subject to communicate with the hospital and for the study team to review potential issues of interest on the patient's asthma control parameters which might need an intervention such us additional in-person consultations

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 y.o. or more. * Diagnosis of asthma, confirmed by spirometry: positive post bronchodilator test (PBT), defined as an improvement of at least 12% and an increment of at least 200 ml in the absolute value of FEV1 following B-agonist inhalation. In case of negative PBT, asthma diagnoses could be establish if a positive result, defined as a PC20\< 8 pgr, was achieved in the Methacholine Challenge Test (MCT). * BMI of 25 or more. * Subjects must meet criteria of acceptability of spirometry in at least in three manoeuvres (within a maximun of 8). Acceptability of a spirometry for this protocol purpose is defined by: a) minimum of 6 second exhalation time; b) no cough detected in the first second of expiration; c) 1 second volume plateau. * Subjects must meet criteria of repeatability of spirometry, defined for this protocol purpose as the three highest accepted FEV1 values to be within 0.10L (100mL) of each other or with a variability of 5% or less. * Subjects with capacity to handle a smartphone device, with incorporated Android system, and to use and input data on the app ASMATIC, designed for this study purposes. * Subjects willing to give voluntary, signed informed consent, in accordance with Good Clinical Practice (GCP) guidelines. Exclusion Criteria: * Subjects with uncontrolled or severe asthma at study entry, defined by at least one of the following criteria: a) FEV1 \<80% of the theorical calculated value and a FEV1/FVC ratio \<75% at study entry; b) any severe asthma exacerbation within the two months previous to study entry; c) systemic corticoid or any biological treatment received in the previous 6 months to study entry. * Any known contraindication for bronchodilator reversibility testing or bronchial provocation tests such us: a) any respiratory tract infection in the previous month to selection; b) pregnancy, lactation or intention to become pregnant during the study; or c) any other contraindication for spirometry found following clinical criteria. * Subjects with any limitation in their capacity to collaborate and comply with study requirements. * Active smokers or ex-smokers in the 6 months previous to study entry. * Subjects currently in immunotherapy treatment or potential candidates for it, including subject suffering a malignant disease. * Subjects with asthma non controlled risk factors. * Subjects with any severe or non controlled pathology that compromise their safety during their participation study.

Locations (1)

Service of Allergology. Hospital Universitario Virgen Macarena

Seville, Spain

Outcomes

Primary Outcomes

Change in % of Forced Expiratory Volume in the first second (FEV1) from baseline to endpoint

Asthma control assessed through the change in % FEV1 from baseline to endpoint in the interventional group and between the interventional and control groups.

Time frame: 1 year

Secondary Outcomes

Change in % FEV1 from baseline to weeks 8 and 24.

Asthma control assessed through the change in % FEV1 from baseline to weeks 8 and 24 within the interventional group and between the interventional and control groups.

Time frame: 6 months

Change in the Tiffenau index (FEV1/FVC (Forced Vital Capacity) from baseline to endpoint.

Asthma control assessed through the change in the Tiffenau index (FEV1/FVC) from baseline to endpoint in the interventional group and between the interventional and control groups.

Time frame: 1 year

Change in the Tiffenau index (FEV1/FVC) from baseline to weeks 8 and 24.

Asthma control assessed through the change in the Tiffenau index (FEV1/FVC) from baseline to weeks 8 and 24 within the interventional group and between the interventional and control groups.

Time frame: 6 months

Change in the Body Mass Index (BMI) (measured in kg/m^2) from baseline to endpoint

Change in BMI (measured in kg/m\^2) from baseline to endpoint. Comparison within the interventional group and between intervention and control group

Time frame: 1 year

Change in abdominal perimeter (measured in cm) from baseline to endpoint

Change in abdominal perimeter (measured in cm) from baseline to endpoint. Comparison within the interventional group and between intervention and control group

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.